Servier today announced longer-term data from the Phase 3 INDIGO trial evaluating VORANIGO® (vorasidenib) versus placebo in patients with Grade 2 mutant isocitrate dehydrogenase 1 or 2 (mIDH1/2) ...
By stimulating cancer cells to produce a molecule that activates a signaling pathway in nearby immune cells, MIT researchers have found a way to force tumors to trigger their own destruction.
A inhibitors does not trigger MACEs when compared with TNF- α inhibitors in the 6 months following treatment initiation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback